PFM's Investment in サイフューズ's Regenerative Medicine Development
First written in FY2022-Q3. 1 of 2 entries say "Restated". Latest entry: FY2022.
0 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「In December 2021, we made a development investment in a development project undertaken by 株式会社サイフューズ (Bunkyo-ku, Tokyo), a regenerative medicine venture.」
We continue to pursue investment in サイフューズ's regenerative medicine product development and support for commercialisation through PFM. - FY2022-Q3First statedAnnual report
「As one of our new businesses, we are also pursuing initiatives under our proprietary business model, PFM (Project Finance & Marketing). In December of the same year, we made a development investment in a development project undertaken by 株式会社サイフューズ (Bunkyo-ku, Tokyo; hereinafter, サイフューズ), a regenerative medicine venture. The investment targets サイフューズ's ongoing development of regenerative medicine products and other products. We will support the commercialisation of this development, contributing to the expansion of products handled in the regenerative medicine field in the future and to improvements in patients' quality of life (QOL).」
As a specific example of our proprietary PFM (Project Finance & Marketing), we made a development investment in サイフューズ's regenerative medicine product development project and began initiatives to support its commercialisation and expand the products we handle in the future.